Milatuzumab Biosimilar - Research Grade

Human

CD74

>1mg/ml

IgG1 - kappa

CHO Cells

Bezetabart Biosimilar - Research Grade (ICH5399)

https://www.imgt.org/mAb-DB/

ICH3002

P04233

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of milatuzumab, a fully human IgG1-kappa antibody directed against CD74 (the invariant chain, Ii; UniProt P04233). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the CD74 target, it is useful as a reference reagent for studying CD74 biology and for antibody-development workflows: as a positive binding control, for competition and epitope-mapping assays, for characterizing CD74 expression on B-cell lymphoma and myeloma lines, and as a benchmarking tool alongside in-house anti-CD74 candidates. Because CD74 rapidly internalizes upon antibody engagement, the analog is also a practical model for internalization and receptor-turnover studies and for antibody-drug-conjugate (ADC) development, where efficient antigen-mediated uptake is desirable. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and in bulk milligram-to-gram quantities to support in-vitro assays and preclinical model work. Suitability should be confirmed for each specific application. CD74, also called the MHC class II invariant chain (Ii), is a type II transmembrane glycoprotein that acts as a chaperone for MHC class II molecules. In the endoplasmic reticulum it assembles with class II alpha-beta dimers, preventing premature peptide binding and directing the complex through the endosomal pathway, where CD74 is proteolytically degraded to the CLIP fragment before antigen-peptide loading. A minor cell-surface pool of CD74 also serves as a high-affinity receptor for macrophage migration inhibitory factor (MIF), triggering CD44/CXCR-linked signaling that promotes cell survival and proliferation. CD74 is expressed on antigen-presenting cells, B cells, monocytes, and dendritic cells, and is frequently overexpressed on B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Its rapid antibody-induced internalization and tumor-associated expression make it an attractive target for antibody and ADC-based approaches.

HLA-DR antigens-associated invariant chain, Ia antigen-associated invariant chain, Ii, HLA class II histocompatibility antigen gamma chain, DHLAG

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Milatuzumab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Milatuzumab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Milatuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Milatuzumab that binds CD74; for research use only.